里程碑｜2022重點總覽 2022 in focus

一月

全球傑出雇主

百靈佳殷格翰再次獲頒全球傑出雇主，公司在薪酬、認同、靈活的工作環境、公司價值觀、道德與誠信上的評選獲得高分，並從29個國家中脫穎而出。

二月

加快BI 1015550的審查

專為特發性肺纖維化研發的口服療法BI 1015550在第二期的試驗中出現了有希望的研究結果，獲得美國食品藥物管理局（FDA）授予突破性治療（BTD）的認可，加速了審查流程。

三月

對症心臟衰竭的JARDIANCE®

JARDIANCE®恩排糖是首個獲得歐洲核可治療成人鬱血性心臟衰竭且不受收縮分率影響的藥物，適用於正常收縮分率心臟衰竭的病症。在此之前，歐洲該類型的病患未能有治療的核可藥物。而在取得歐洲藥物核可前，該藥已經通過美國食品藥物管理局（FDA）的審核。

四月

全新馬用幹細胞療法

百靈佳殷格翰推出的RenuTend™, 是一款用於改善馬匹肌腱與懸吊韌帶損傷癒合的新幹細胞療法。單劑量可改善纖維排列，減少疤痕組織生成，RenuTend™ 將可在歐盟區域上市。

五月

TwistPak®可快速有效地為豬隻接種疫苗

獲獎設計與專利技術：TwistPak®鮮轉瓶可在五秒內混合Ingelvac CircoFLEX® 百靈佳環狀病毒不活化疫苗和 Ingelvac MycoFLEX® 百靈佳豬黴漿菌肺炎不活化菌苗疫苗，可以更輕鬆操作，減輕了豬隻畜牧業者的工作量，並提高豬隻的健康。

六月

與CarthroniX 合作

百靈佳殷格翰與CarthroniX合作研究，CarthroniX 是一間專門研發退化性與年齡相關疾病低分子療法的生物製藥公司，兩間公司將攜手研發犬科種療治療的低分子藥物。

七月

Aurobac： 合作對抗微生物抗藥性（AMR）

百靈佳殷格翰、生命科學公司Evotec以及引領全球的體外診斷醫療器材供應商bioMérieux宣布合資成立公司，該公司名為Aurobac Therapeutics ，三者將共同開發一種對抗微生物抗藥性的新方法。

八月

百靈佳殷格翰的研究於2022上半年取得初步進展

2022上半年，百靈佳殷格翰在經濟、政治與環境法規日益艱困的情況下，持續為患者改善藥物供應，以及擴大研發管道。由於人類心臟衰竭、糖尿病與呼吸系統疾病的產品及動物用藥需求增加，除去匯率等因素，淨銷售額成長了9.5%，達到了112億歐元。

九月

美國藥物管理局（FDA）首次通過全身型膿疱性乾癬療法

美國公共衛生署成為第一個核可spesolima用於治療成年人全身型膿疱性乾癬（GPP）的管理機構，透過阻斷免疫系統中影響全身型膿疱性乾癬 （GPP）表現的介白素36（IL-36R）的受體進行治療，這個創新的選擇性抗體在美國市場以SPEVIGO®的名義推出。公司在十月份向歐洲藥物管理局提交了上市授權申請，目前處於評估的階段。

十月

攜手共創健康：虛實整合的國際會議

在《 MMH計畫 》的號召下，人們第二次在德國Ingelheim 、肯亞Nairobi 以及虛擬世界中會面，，一起交流實際可行的點子，並建立夥伴關係，共同解決當下全球最緊迫的健康議題。《 MMH計畫 》源於百靈佳殷格翰與全球最大的社會創新企業家網絡Ashoka的合作，面對複雜的醫療保健問題，以創新、專業的能力創造更永續且全面的解決方案。

投資初創社會企業Cowtribe

Cowtribe是位於迦納（Ghana）的一家物流公司，也是百靈佳殷格翰Social Engagement（BI SE）計畫中首位獲得投資與非財務支援的受益者。該計畫旨在協助弱勢地區社會企業的資金瓶頸。身為初創社會企業的Cowtribe，透過創新的方式（例如：以程式軟體處理需求與供應的媒合，或採用無人機進行遞送的合作），為偏遠地區的小農及獸醫搭建了所需物品的橋樑，解決了物流最後一哩路的難題。

十一月

公佈EMPA-KIDNEY 試驗的完整成果

EMPA-KIDNE是首個應用於慢性腎臟病之第三期臨床試驗，證明對任何原因住院的風險有統計學意義上的顯著降低，可緩解病人的症狀，並減輕醫療系統的負擔。作為迄今SGLT2抑制劑研究中規模最大、族群範圍最廣的試驗，其涵蓋的慢性腎臟病族群，反映了在過往的SGLT2抑制劑試驗中被忽略的成年腎臟病病患，有助解決這項至關重要卻未被滿足的需求。

MILESTONES 2022 in focus

January

Global Top Employer

Boehringer Ingelheim is once again a Global Top Employer! Scoring particularly high in the area of rewards and recognition as well as agile work environment, company’s values, ethics and integrity, the company received the award in 29 countries.

February

Accelerated approval of BI 1015550

Following promising study results in Phase II, the U.S. regulatory authority, the Food & Drug Administration (FDA), grants the substance BI 1015550 Breakthrough Therapy Designation (BTD) status as an oral therapy for idiopathic pulmonary fibrosis, thus clearing the way for an accelerated approval process.

March

JARDIANCE® for heart failure

JARDIANCE® (empagliflozin) is the first and only medicine to be approved in Europe for treatment of adults with chronic heart failure independent of the ejection fraction. This extends the existing indication to adults with heart failure with preserved ejection fraction, an underserved patient group for whom no approved therapies have previously existed in Europe. The European approval follows approval by the U.S. Food & Drug

April

New stem cell therapy for horses

Boehringer Ingelheim launches RenuTend™, a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses. A single dose improves fiber alignment and decreases scar tissue formation. RenuTend™ will be available across the European Union.

May

Fast and effective swine vaccination with TwistPak®

Prize-winning design and patented technology: TwistPak® makes it possible to mix Ingelvac CircoFLEX® and Ingelvac MycoFLEX® vaccines in less than five seconds – easily, flexibly while decreasing the workload for swine producers and increasing the well-being of pigs.

June

Partnership with CarthroniX

Boehringer Ingelheim and CarthroniX announce a research partnership. CarthroniX is a biopharmaceutical company that focuses on the development of low-molecular therapies for degenerative and age-related diseases. The companies intend to work together to develop low-molecular therapies for oncology in dogs.

July

Aurobac: joint venture for the fight against AMR

Boehringer Ingelheim, life science company Evotec and bioMérieux, one of the world’s leading providers of in vitro diagnostics, announce the establishment of a joint venture. The joint company, Aurobac Therapeutics, will develop a new approach to combating anti-microbial resistance.

August

Boehringer Ingelheim makes fundamental progress in research and development

In the first half of 2022, Boehringer Ingelheim continued to improve the supply of medicines to patients and expanded its research pipeline in an increasingly difficult economic, political and regulatory environment. Thanks to continued strong demand for products to treat heart failure, diabetes and respiratory diseases in humans as well as products for pets, currency-adjusted net sales increased by 9.5 percent to 11.2 billion euros.

September

FDA approves therapy for GPP flare-ups in adults for the first time

The U.S. public health authority is the first regulatory authority to approve spesolimab for the treatment of generalized pustular psoriasis (GPP) in adults. The innovative, selective antibody is marketed in the USA as SPEVIGO®. It blocks activation of the interleukin-36 receptor (IL-36R), a pathway in the immune system that is verifiably involved in the development of GPP. In October the company’s marketing authorization application for spesolimab was validated by and is now under evaluation with the European Medicines Agency.

October

Making More Health Together:international hybrid convention

For the second time and under the umbrella of Making More Health(MMH),people met in Ingelheim(Germany),Nairobi(Kenya) as well as virtually,to exchange action-oriented ideas and to build partnerships with the goal of addressing the most urgent global health issues of our time. MMHis a long-term partnership between Boehringer Ingelheim and Ashoka, the world's largest network of social entrepreneurs. It combines

invovative socio-entrepreneurial solutions with business expertise to meet complex health care challenges,thereby creating more sustainable global solutions.

Social start-up Cowtribe receives investment

Cowtribe,a leading last-mile veterinary delivery company forem Ghana,is the first recipinet of investment and non-financial suppport from the Boehringer Ingelheim Social Engagement(BI SE) initiative.The program aims to close a critical financing gap for social businesses in vulnerable communities. Cowtribe is a social start-up the bridges the final, critical last mile to get animal medication and veterinary vaccines to smallholder farmers in remote areas by using innovative solutions,such as software supported demand and supply matching,as well as a partnership for drone delivery.

November

EMPA-KIDNEY trial full results disclosed

EMPA-KIDNEY is the first Phase III chronic kidney disease trial to demonstrate a statistically significant reduction in hospitalization for any cause, bringing relief for patients and reducing burden on healthcare systems. The largest and broadest dedicated SGLT2 inhibitor CKD trial to date, it is reflective of the CKD population, including adults with CKD who have been historically under-represented in previous SGLT2 inhibitor trials, addressing a critical unmet need.